Wynclark Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 14.08 Cr
as on 24-10-2024
- Paid Up Capital ₹ 14.08 Cr
as on 24-10-2024
- Company Age 17 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 40.13%
(FY 2023)
- Profit 24.69%
(FY 2023)
- Ebitda 50.81%
(FY 2023)
- Net Worth 61.48%
(FY 2023)
- Total Assets 17.67%
(FY 2023)
About Wynclark Pharmaceuticals
The Corporate was formerly known as Medplus Smart Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 14.08 Cr and a paid-up capital of Rs 14.08 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Wynclark Pharmaceuticals Private Limited India are Sujit Mahato as CFO and Riti Gupta as Company Secretary. Paidiwar Srinivas, Bhaskar Cherukupalli, and Satya Kammila serve as directors at the Company.
- CIN/LLPIN
U24239TG2007PTC052676
- Company No.
052676
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Feb 2007
- Date of AGM
10 Jul 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Wynclark Pharmaceuticals?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sujit Mahato  | CFO | 16-Nov-2022 | Current |
| Riti Gupta | Company Secretary | 10-Jan-2023 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Paidiwar Srinivas | Director | 03-Aug-2013 | Current |
| Bhaskar Cherukupalli | Director | 29-Sep-2021 | Current |
| Satya Kammila | Whole-Time Director | 29-Sep-2021 | Current |
Financial Performance and Corporate Structure Insights of Wynclark Pharmaceuticals.
Wynclark Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 40.13% increase. The company also saw a substantial improvement in profitability, with a 24.69% increase in profit. The company's net worth Soared by an impressive increase of 61.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Wynclark Pharmaceuticals?
In 2023, Wynclark Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Mhs Pharmaceuticals Private LimitedActive 16 years 6 monthsPaidiwar Srinivas and Bhaskar Cherukupalli are mutual person
- Medplus Health Services LimitedActive 18 years 20 days
Bhaskar Cherukupalli and Sujit Mahato are mutual person
- Madhukar Gangadi Ventures Private LimitedActive 5 years 8 months
Bhaskar Cherukupalli is a mutual person
- Lone Furrow Investments Private LimitedActive 4 years 1 month
Bhaskar Cherukupalli is a mutual person
Kalyani Meditimes Private LimitedActive 8 years 4 monthsBhaskar Cherukupalli and Satya Kammila are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Wynclark Pharmaceuticals?
Wynclark Pharmaceuticals has a workforce of 7 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Wynclark Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wynclark Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
